Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36239337)

  • 1. Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer.
    Choi SH; Do SK; Lee SY; Choi JE; Kang HG; Hong MJ; Lee JH; Lee WK; Jeong JY; Shin KM; Do YW; Lee EB; Park JE; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Thorac Cancer; 2022 Dec; 13(23):3322-3330. PubMed ID: 36239337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
    Choi SH; Jin CC; Do SK; Lee SY; Choi JE; Kang HG; Kim JH; Lee JH; Hong MJ; Lee WK; Jeong JY; Shin KM; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Oncology; 2020; 98(7):468-477. PubMed ID: 32252059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet.
    Ryu JS; Lim JH; Kim HJ; Kim MJ; Park MH; Kim JS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30842342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
    Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
    Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
    Seo H; Jung DK; Kang HG; Jeong JY; Lee SY; Choi JE; Hong MJ; Do SK; Lee JH; Lee WK; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Cancer Genet; 2018 Dec; 228-229():73-82. PubMed ID: 30553476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogic acid.
    Li X; Tang X; Su J; Xu G; Zhao L; Qi Q
    Biochem Pharmacol; 2019 Nov; 169():113635. PubMed ID: 31513784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
    Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
    PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition.
    Jin HO; Hong SE; Woo SH; Lee JH; Choe TB; Kim EK; Noh WC; Lee JK; Hong SI; Kim JI; Park IC
    Cell Death Dis; 2012 Jun; 3(6):e319. PubMed ID: 22673193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer.
    Lee SJ; Kang BW; Chae YS; Kim HJ; Park SY; Park JS; Choi GS; Jeon HS; Lee WK; Kim JG
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S634-9. PubMed ID: 24770722
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Vernieri C; Ganzinelli M; Rulli E; Farina G; Bettini AC; Bareggi C; Rosso L; Signorelli D; Galli G; Lo Russo G; Proto C; Moro M; Indraccolo S; Busico A; Sozzi G; Torri V; Marabese M; Massimo B; Garassino MC
    ESMO Open; 2020 May; 5(3):e000748. PubMed ID: 32467099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
    Han D; Li SJ; Zhu YT; Liu L; Li MX
    Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
    Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective.
    Ciccarese F; Zulato E; Indraccolo S
    Oxid Med Cell Longev; 2019; 2019():8730816. PubMed ID: 31781355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.